Hoe Pharma Of Malaysia Seeks European Joint Ventures
This article was originally published in PharmAsia News
Malaysia's Hoe Pharma Holdings says it is seeking joint ventures with European counterparts to enhance its presence in the European market. Hoe CEO B.K. Lee said his firm, a dermatological product specialist, is looking for ties with a European pharmaceutical companies that would hold majority interest there and a corresponding venture in Malaysia in which Hoe would hold majority interest. He said he hopes to sign such a deal next year, giving Hoe a new range of products to market. A unit of Goldis, Hoe specializes in over-the-counter products and ethical drugs, mainly prescription-based. (Click here for more
You may also be interested in...
New report shows average out-of-pocket cost per prescription of $10.67 in 2019 was unchanged from 2018. But while the number of dispensed drugs barely increased, sales jumped more than 5%.
The merger between virtual care companies Teladoc and Livongo will offer individuals a wide range of tech-enabled care during a time when telehealth continues to grow.
Regeneron's antibody cocktail for SARS-Cov-2 is largely in holding mode for now, but the company announced progress on other fronts including for Dupixent in COPD and the NGF inhibitor fasinumab.